- Home
- NCPL vs PCSA Comparison
NCPL vs PCSA Comparison
Compare NCPL & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- PCSA
- Stock Information
- Founded
- NCPL 1984
- PCSA 2011
- Country
- NCPL United States
- PCSA United States
- Employees
- NCPL N/A
- PCSA N/A
- Industry
- NCPL Investment Managers
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- PCSA Health Care
- Exchange
- NCPL Nasdaq
- PCSA Nasdaq
- Market Cap
- NCPL 3.4M
- PCSA 2.8M
- IPO Year
- NCPL N/A
- PCSA N/A
- Fundamental
- Price
- NCPL $1.88
- PCSA $0.45
- Analyst Decision
- NCPL
- PCSA Strong Buy
- Analyst Count
- NCPL 0
- PCSA 1
- Target Price
- NCPL N/A
- PCSA $6.00
- AVG Volume (30 Days)
- NCPL 104.5K
- PCSA 108.6K
- Earning Date
- NCPL 03-21-2025
- PCSA 03-28-2025
- Dividend Yield
- NCPL N/A
- PCSA N/A
- EPS Growth
- NCPL N/A
- PCSA N/A
- EPS
- NCPL N/A
- PCSA N/A
- Revenue
- NCPL $1,702,723.00
- PCSA N/A
- Revenue This Year
- NCPL N/A
- PCSA N/A
- Revenue Next Year
- NCPL $101.16
- PCSA N/A
- P/E Ratio
- NCPL N/A
- PCSA N/A
- Revenue Growth
- NCPL N/A
- PCSA N/A
- 52 Week Low
- NCPL $1.41
- PCSA $0.44
- 52 Week High
- NCPL $22.82
- PCSA $3.31
- Technical
- Relative Strength Index (RSI)
- NCPL 36.12
- PCSA 28.60
- Support Level
- NCPL $1.85
- PCSA $0.44
- Resistance Level
- NCPL $2.25
- PCSA $0.54
- Average True Range (ATR)
- NCPL 0.15
- PCSA 0.05
- MACD
- NCPL -0.05
- PCSA 0.00
- Stochastic Oscillator
- NCPL 5.45
- PCSA 8.02
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).